Quantity size:
0.2ml
Concentration:
1mg/ml 原癌基因FRAT1抗体 Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) 原癌基因FRAT1抗体binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates 原癌基因FRAT1抗体and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
原癌基因FRAT1抗体Also known as:
FRAT 1; frequently rearranged in advanced T cell lymphomas; Frequently rearranged in advanced T-cell lymphomas; GSK 3 binding protein FRAT1; proto oncogene FRAT1; FRAT1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Cow, .
●
Immunogen: KLH conjugated synthetic peptide derived from human FRAT1.
●
Predicted Molecular Weight: 29kDa.
原癌基因FRAT1抗体Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
kl263Mu01精氨酸加压素受体1B(AVPR1B)多克隆抗体Polyclonal Antibody to Arginine Vasopressin Receptor 1B (AVPR1B)
kl265Hu01胰多肽(PP)多克隆抗体Polyclonal Antibody to klcreatic Polypeptide (PP)
kl265Mu01胰多肽(PP)多克隆抗体Polyclonal Antibody to klcreatic Polypeptide (PP)
kl266Ga01胰高血糖素(GC)多克隆抗体Polyclonal Antibody to Glucagon (GC)
kl267Hu01激肽原1(KNG1)多克隆抗体Polyclonal Antibody to Kininogen 1 (KNG1)
kl267Mu01激肽原1(KNG1)多克隆抗体Polyclonal Antibody to Kininogen 1 (KNG1)
kl267Ra01激肽原1(KNG1)多克隆抗体Polyclonal Antibody to Kininogen 1 (KNG1)
kl268Hu01苯酚磺基转移酶(PST)多克隆抗体Polyclonal Antibody to Phenol Sulfotransferase (PST)
kl268Mu01苯酚磺基转移酶(PST)多克隆抗体Polyclonal Antibody to Phenol Sulfotransferase (PST)
kl271Hu01IgG-Fc片段低亲和力受体Ⅲb(FcγR3B)多克隆抗体Polyclonal Antibody to Fc Fragment Of IgG Low Affinity IIIb Receptor (FcgR3B)
kl273Hu01孕酮受体(PGR)多克隆抗体Polyclonal Antibody to Progesterone Receptor (PGR)
kl275Hu01膜辅蛋白(MCP)多克隆抗体Polyclonal Antibody to Membrane Cofactor Protein (MCP)
kl276Hu01激素敏感性脂肪酶(LIPE)多克隆抗体Polyclonal Antibody to Likle, Hormone Sensitive (LIPE)
kl276Ra01激素敏感性脂肪酶(LIPE)多克隆抗体Polyclonal Antibody to Likle, Hormone Sensitive (LIPE)
kl277Hu01脑型脂肪酸结合蛋白(FABP7)多克隆抗体Polyclonal Antibody to Fatty Acid Binding Protein 7, Brain (FABP7)
kl278Hu01IgG-Fc片段低亲和力受体Ⅲa(FcγR3A)多克隆抗体Polyclonal Antibody to Fc Fragment Of IgG Low Affinity IIIa Receptor (FcgR3A)
kl280Bo01组织蛋白酶D(CTSD)多克隆抗体Polyclonal Antibody to Cathepsin D (CTSD)
kl280Hu01组织蛋白酶D(CTSD)多克隆抗体Polyclonal Antibody to Cathepsin D (CTSD)
kl280Mu01组织蛋白酶D(CTSD)多克隆抗体Polyclonal Antibody to Cathepsin D (CTSD)
更多
企业名称
上海康朗生物科技有限公司
企业信息已认证
企业类型
信用代码
310112001510759
成立日期
2015-05-29
注册资本
100
经营范围
从事生物科技技术领域内技术开发、技术咨询、技术服务、技术转让,实验分析仪器、化工产品及原料(除危险化学品、监控化学品、烟花爆竹、民用爆竹物品、易制毒化学品)、仪器仪表、环保设备、酒店用品、皮革制品、床上用品、电子产品的销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上海康朗生物科技有限公司
公司地址
上海市闵行区闵北路88弄1-30号第22栋BV145室
客服电话